Li Y, et al. - Via performing a multicentre, open-label, non-inferiority, two-group randomized controlled trial in eight counties or districts in China, researchers examined how the immunogenicity of measles-rubella vaccine is affected when co-administered with attenuated Japanese encephalitis SA 14–14–2 vaccine at 8 months of age. Healthy infants aged 8 months who had received all scheduled vaccinations according to the national immunisation recommendations were randomly assigned (1:1) to receive either measles-rubella vaccine and live attenuated SA 14–14–2 Japanese encephalitis vaccine (LJEV) simultaneously (measles-rubella plus LJEV group) or measles-rubella vaccine alone (measles-rubella group); the measles-rubella plus LJEV group included 545 infants and the measles-rubella group included 548 infants. The evidence demonstrates similar seroconversion and safety with co-administered LJEV and measles-rubella vaccines. This supports the co-administration of these vaccines to infants aged 8 months.